Notice of Results

Alliance Pharma PLC
26 April 2004


FOR IMMEDIATE RELEASE                                            26th April 2004


                              ALLIANCE PHARMA PLC

                        PRELIMINARY Results Announcement

                                   Wednesday

                                 12th May 2004



Alliance Pharma plc, the emerging speciality pharmaceutical company, will be
announcing its preliminary results for the 12 months to 28th February 2003 and
update analysts on the progress of its two development projects, on Wednesday
12th May.  On the day the Company will hold a presentation for analysts.  The
presentation will start at 11.30am and will be followed by a buffet lunch.  The
details are as follows:


Date:          12th May 2004
Time:          11.15 am for 11.30 am
Venue:         Number1 Cornhill
               London
               EC3V 3ND

Alliance Pharma, founded in 1996, is an AIM listed emerging speciality
pharmaceutical company based in Chippenham, Wiltshire.  The company has a strong
track record of acquiring the rights to established niche brands and owns, or
shares, the rights to 27 branded pharmaceutical products and is currently
exploring several opportunities to expand the range.  In November 2003 the
company acquired Peerless Technology Group Plc constituting a reverse takeover
under the AIM rules.

This is an interesting small company and the meeting will provide an opportunity
to meet the management team at an early stage in its career as a public company.
The preliminary figures will be released at 7.00 am that morning.

Alliance's products are prescribed in the treatment of a wide range of
conditions and include brands used in the prevention of heart disease, in
Parkinson's disease, in nasal infections, in the treatment of dermatological
conditions and in childbirth.  Alliance's sales are mainly prescription driven.
They are distributed to hospitals directly and to pharmaceutical wholesalers who
service both hospital and retail pharmacies with their prescription
requirements.


For further information contact:


Beattie Financial                                                  020 7398 3300
Mike Wort/JamesChandler/John Moriarty


                      This information is provided by RNS
            The company news service from the London Stock Exchange